Intra-amniotic infection is a common occurrence in pregnant women, which affects both the mother and baby. Intra-amniotic infection is also known as chorioamnionitis. The incidence is high at lower gestational ages. The main mechanism for intra-amniotic infection is projected to be the ascending bacterial infection from the maternal genital tract. Intra-amniotic infection is the inflammatory process that mainly affects the chorioamniotic membrane, umbilical cord and the fetus. The intra-amniotic infection is associated with symptoms such as fever, uterine tenderness, and foul smelling amniotic fluid. If the treatment is not given at proper time the patient may develop severe complications of intra-amniotic infection such as still birth, cerebral palsy, preterm premature rupture of membrane.
To remain ‘ahead’ of your competitors, request a sample https://www.factmr.com/connectus/sample?flag=S&rep_id=2184
The standard treatment recommended for intra-amniotic infection includes antibiotic therapies. The antibiotics are given in various combinations depending upon the duration of pregnancy such as intrapartum and postpartum. Alternative therapies such as prophylaxis and diet modification may provide symptomatic relief and prevent recurrence, but are recommended along with standard antibiotics. Ampicillin and gentamicin are commonly recommended antibiotics for intra-amniotic infection. The polymicrobial intra-amniotic infection is confirmed by pathological tests such as gram staining, glucose level and histological evidence of placental infection.
Intra-amniotic Infection Treatment Market: Drivers and Restraints
The global intra-amniotic infection treatment market is primarily driven by the increasing prevalence and recurrence of intra-amniotic infection across the globe. The disorder is common in women with lower gestational ages, which is the major factor expected to drive the growth of the intra-amniotic infection treatment market. The CDC and American Pediatrics Association have provided guidelines for assessing risk of neonatal infection. The guidelines recommend to conduct laboratory studies and empiric antibiotic therapy, which has led the pharmaceutical companies to launch new range of products for the treatment. Overall, the antibiotic-based treatment therapy will remain the first line of treatment for intra-amniotic infection, contributing majorly to the growth of the global intra-amniotic infection treatment market. Rapid increase in diagnostic procedures such as proteomic profiling and identification of novel biomarkers is further expected to surge the demand for intra-amniotic infection treatment over the forecast period.
Speak To Research Analyst For Detailed Insights: https://www.factmr.com/connectus/sample?flag=AE&rep_id=2184
Intra-amniotic Infection Treatment Market: Segmentation
Tentatively, the global intra-amniotic infection treatment market can be segmented on the basis of treatment types and end users.
Based on treatment types, the global intra-amniotic infection treatment market is segmented as:
- Ampicillin/ Sulbactam
Based on end users, the intra-amniotic infection treatment market is segmented as:
- Hospital and Specialty Clinics
- Ambulatory Surgical Centers
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- E- commerce
Intra-amniotic Infection Treatment Market: Overview
Several antibiotics are used for the treatment of intra-amniotic infection, but Metronidazole (Flagyl) by Pfizer is the most commonly used antibiotic, as it crosses the placental barrier and enters the fetal circulation rapidly, which is expected to fuel the growth of the therapeutics segment. Changes is lifestyle and eating habits are attributed to growing prevalence of intra-amniotic infection. In the upcoming years, the global intra-amniotic infection treatment market is expected to witness entry of new market players, which would increase the competition.
For critical insights on this market, request for methodology here https://www.factmr.com/connectus/sample?flag=RM&rep_id=2184
Intra-amniotic Infection Treatment Market: Regional Outlook
On the basis of geography, the global intra-amniotic infection treatment market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is expected to hold large revenue share in the global intra-amniotic infection market primarily due to increasing prevalence of intra-amniotic infection, growing investment in the healthcare sector and increasing awareness among the general population regarding intra-amniotic infection treatments. In addition, improved living conditions and health care initiatives by governing bodies are factors expected to fuel the growth of the intra-amniotic infection treatment market in Latin America. Western Europe followed by Asia Pacific is expected to be the second fast-growing regional market for intra-amniotic infection treatment.
Intra-amniotic Infection Treatment Market: Key Players
Examples of some of the key players operating in the global intra-amniotic infection treatment market are Pfizer limited, Max cure drugs and pharmaceutical Ltd, Zydus cadila healthcare Ltd., Cipla Limited, and Aristopharma Ltd., among others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies Involved
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico, Brazil, Argentina, Peru, Chile, Rest of LATAM)
- Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Eastern Europe, Rest of Europe)
- CIS & Russia
- Asia Pacific Excluding Japan ( Greater China, India, South Korea, ASEAN Countries, Rest of APEJ)
- Middle East and Africa (GCC Countries, Turkey, Iran, Israel, S. Africa, Rest of MEA)
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583